HIF1A and pulmonary hypertension: In general, at least 12 different pharmacological inhibitors of HIF1 and HIF2α were able to attenuate, prevent or reverse experimental pulmonary hypertension in rats or mice [reviewed in (157)] and multiple strategies appear feasible: Besides pharmacological inhibition of HIF signaling, destabilization of HIF via activation of HIF-degrading enzyme cascades or disruption of HIF complexes have all shown promising results as potential therapeutic strategies in experimental PH (and, partly, in ECs isolated from PAH patients) (208–210).